Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 10, 2010, Pages 1715-1726

  Olsson, Anders G ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Stockholm Heart Center   (Sweden)

Author keywords

Apolipoproteins; Atherosclerosis; Cardiovascular disease; Cholesterol; Flushing; Laropiprant; Lipoproteins; Niacin; Nicotinic acid; Prevention; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; ACIPIMOX; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHYLOMICRON; CLOFIBRATE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOMETACIN; INTERMEDIATE DENSITY LIPOPROTEIN; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICERITROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; NICOTINIC ACID PLUS SIMVASTATIN; TREDAPTIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EVENING DOSAGE; FLUSHING; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; NONHUMAN; RETINA EDEMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FLUSHING; HUMANS; INDOLES; LIPID METABOLISM; NIACIN;

EID: 77953642707     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.489894     Document Type: Review

References (29)

1. Altschul R, Hoffer A, Stephen J. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955;54:558-559
2. Parsons WJ, Flinn J. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch Intern Med 1959;103:783-790
3. Carlson L, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-276
4. Carlson L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
5. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis 1978;30:239-240
6. Canner P, Berge K, Wenger N, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255
7. Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418
8. Blankenhorn DH, Selzer RH, Crawford DW, et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-28
9. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592
10. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361(22):2113- 2122 .. The most recent study on the effect of adding niacin to statin treatment, demonstrating better effect on carotid atherosclerosis as estimated by ultrasound than adding ezetimibe.
11. Lee JMS, Robson MD, Yu L-M, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-1794
12. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intimaa-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-2250
13. Carlson L, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962;172:641-645
14. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-355 .. First description of the niacin receptor.
15. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008;101(8 Suppl 1):S20-6
16. Jin F-Y, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-2028
17. Lamon-Fava S, Diffenderfer MR, Barrett PHR, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apo B-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:1672-1678
18. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31:149-164
19. Benyó Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-3640
20. Cheng K, Wu T-J, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103(17):6682-6687 .. First description of the DP1 receptor antagonist laropiprant.
21. Morrow J, Awad J, Oates J, Roberts LN. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992;98:812-815
22. Paolini J, Bays H, Ballantyne C, et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008;26:547-560 .. First description of the effect of flush inhibition by laropiprant in man.
23. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/ laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-1970
24. Carlson L, Olsson A. Effect of hypolipidemic drugs on serum lipoproteins. Prog Biochem Pharmacol 1979;15:238-257
25. Norquist JM, Watson DJ, Yu Q, et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007;23:1549-1560
26. Kaijser L, Eklund B, Olsson A, Carlson L. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979;57:114-117
27. Lai E, Schwartz JI, Dallob A, et al. Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21(3):191-198
28. Lauring B, Dishy V, Luo W-L, et al. Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-1435
29. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435